Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • 2-Deoxy-D-glucose (2-DG): Precision Glycolysis Inhibition...

    2026-03-06

    2-Deoxy-D-glucose (2-DG): Precision Glycolysis Inhibition in Cancer and Viral Research

    Executive Summary: 2-Deoxy-D-glucose (2-DG), supplied by APExBIO (SKU B1027), is a competitive glycolysis inhibitor that impairs glucose metabolism and ATP synthesis[product]. 2-DG demonstrates potent cytotoxicity against KIT-positive gastrointestinal stromal tumor (GIST) cell lines (IC50 0.5–2.5 μM) and enhances the efficacy of standard chemotherapeutics in animal models. It inhibits viral replication, notably suppressing PEDV protein translation in Vero cells, and is soluble at ≥105 mg/mL in water. Typical research protocols use 5–10 mM for 24-hour treatments. These properties make 2-DG a cornerstone tool for metabolic, cancer, and virology studies (Chen et al., 2025).

    Biological Rationale

    Cellular energy homeostasis is maintained through glycolysis and oxidative phosphorylation. Cancer cells and virally infected cells often upregulate glycolytic flux (the "Warburg effect") to support rapid proliferation and biosynthesis[1]. Inhibiting glycolysis selectively induces metabolic stress in these cells. 2-Deoxy-D-glucose, a glucose analog, cannot undergo complete glycolytic processing, resulting in ATP depletion and metabolic arrest. As a result, 2-DG is valued in oncology and virology for targeting altered metabolic states (compare: Balaglitazone.com—this article extends prior coverage with updated cytotoxicity benchmarks and viral data).

    Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

    2-DG enters cells via glucose transporters and is phosphorylated by hexokinase to 2-DG-6-phosphate. However, 2-DG-6-phosphate cannot be further metabolized by phosphohexose isomerase, resulting in product accumulation and feedback inhibition of glycolytic enzymes[1]. This competitive inhibition disrupts glycolytic flux, reduces pyruvate and lactate output, and decreases ATP synthesis. Secondary consequences include activation of cellular stress responses (e.g., AMPK), altered redox balance, and modulation of signaling pathways such as PI3K/Akt/mTOR. In virally infected cells, 2-DG impairs viral protein glycosylation and translation, limiting viral replication during early infection stages.

    Evidence & Benchmarks

    • 2-DG exhibits cytotoxic effects in KIT-positive GIST cell lines, with IC50 values of 0.5 μM (GIST882) and 2.5 μM (GIST430) in vitro (APExBIO product data).
    • In Vero cell models, 2-DG inhibits porcine epidemic diarrhea virus (PEDV) replication and suppresses viral gene expression by impairing glycoprotein translation (Chen et al., 2025).
    • In mouse xenograft models, 2-DG combined with Adriamycin or Paclitaxel slows tumor growth in human osteosarcoma and non-small cell lung cancer lines (APExBIO).
    • 2-DG is highly soluble: ≥105 mg/mL in water, ≥2.37 mg/mL in ethanol (with warming/ultrasonic), and ≥8.2 mg/mL in DMSO (APExBIO).
    • Typical experimental protocols use 5–10 mM 2-DG for 24-hour treatments to induce metabolic oxidative stress in vitro (compare: Carfilzomib-pr-171.com—this article specifies practical dosing and storage guidance).

    Applications, Limits & Misconceptions

    2-Deoxy-D-glucose is widely employed in:

    • Cancer metabolism research: Dissects glycolytic dependencies and metabolic vulnerabilities in tumor cells.
    • Antiviral assays: Evaluates effects on viral replication, especially for enveloped RNA viruses reliant on host glycolysis.
    • Metabolic pathway analysis: Serves as a metabolic probe in cell viability, proliferation, and cytotoxicity assays (contrast: Staurosporine.net—this article details quantitative benchmarks and solution stability).
    • Signal transduction studies: Used to modulate PI3K/Akt/mTOR, AMPK, and related signaling axes.

    2-DG is best suited for in vitro and animal model studies. Its clinical use is limited by potential toxicity and non-specific effects in normal tissues. It is not a substitute for targeted kinase inhibitors or immunotherapies.

    Common Pitfalls or Misconceptions

    • 2-DG does not fully block all glucose metabolism; cells may compensate via alternative pathways (e.g., glutaminolysis).
    • High concentrations (>20 mM) can cause non-specific cytotoxicity unrelated to glycolysis inhibition.
    • 2-DG is not inherently selective for cancer/viro-infected cells and may impact normal proliferative tissues.
    • It is not a direct inducer of apoptosis; effects are mediated via metabolic stress and ATP depletion.
    • Long-term storage of 2-DG solutions is not recommended due to hydrolysis and potency loss (APExBIO).

    Workflow Integration & Parameters

    2-DG can be readily incorporated into cell culture, cytotoxicity, and metabolic flux assays. Prepare fresh 2-DG solutions in water (≥105 mg/mL), DMSO, or ethanol (product details). Store solid at -20°C and use solutions promptly. Standard protocols use 5–10 mM for 24 hours, though dosing may be titrated based on cell type and endpoint. For viral studies, apply 2-DG during early infection stages to assess effects on protein translation and replication. Integrate with readouts such as ATP assays, lactate quantification, or viability staining. APExBIO's high-purity 2-DG is validated for these applications.

    Conclusion & Outlook

    2-Deoxy-D-glucose (2-DG) remains a robust, reproducible tool for dissecting glycolytic metabolism in cancer and virology research. Its well-defined mechanism, solubility profile, and cytotoxic benchmarks support widespread use as a metabolic pathway inhibitor. Ongoing research explores synergistic combinations with chemotherapeutics and immunomodulators. For up-to-date data on precision reprogramming and translational strategies using 2-DG, reference recent expert articles (see: Staurosporine.net—this article updates mechanistic and workflow integration guidance). For validated, high-purity 2-DG, see the APExBIO product page.